Fufang Luobu Mapian (复方罗布麻片Ⅰ)复方罗布麻片Ⅰ

This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。

Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。

生产企业Manufacturer

主要成分Active Ingredients

药物知识说明

罗布麻煎剂干粉是一种在国家药监局注册认定的药品。该药品含有三硅酸镁、双肼酞嗪、异丙嗪-0d3ed55b等成分。

该药品关联的活性成分包括:三硅酸镁Sangui Suanmei、双肼酞嗪Shuangjing Taiqin、异丙嗪Yibing Qin、氢氯噻嗪Qinglv Saiqin、泛酸钙Fansuan Gai。这些成分信息来自国家药监局数据库。

该药品标注的生产企业为:山西华康药业股份有限公司Chinese legal name: 山西华康药业股份有限公司。

您可以探索含有相同成分的其他药品:三硅酸镁-06079ab6成分药品。

本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。

Medicine Knowledge

This medicine (original name: 复方罗布麻片Ⅰ) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).

Active ingredients associated with this product: 三硅酸镁Sangui Suanmei, 双肼酞嗪Shuangjing Taiqin, 异丙嗪Yibing Qin, 氢氯噻嗪Qinglv Saiqin, 泛酸钙Fansuan Gai.

Manufacturers recorded for this product: 山西华康药业股份有限公司Chinese legal name: 山西华康药业股份有限公司.

Explore other medicines containing the same ingredient: 三硅酸镁 productsProducts containing this recorded ingredient.

Source: MedicineGraph authoritative database. Relationships derived from registered product information.

这是什么What is this

  • 通用名/品名Recorded product name: 复方罗布麻片ⅠRecorded Chinese name: 复方罗布麻片Ⅰ
  • 规格Specification: 复方Recorded Chinese specification

本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.

生产企业Manufacturer

  • 山西华康药业股份有限公司Chinese legal name: 山西华康药业股份有限公司

注册信息NMPA approval number

  • 批准文号NMPA approval number: 国药准字H14022935

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.

  • 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
  • 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.

本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.

English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.

NMPA approval number

国药准字H14022935

Manufacturer

Chinese legal name: 山西华康药业股份有限公司 (domestically manufactured)

Indications

English translation unavailable. The original Chinese source label remains available below.

Dosage and administration

English translation unavailable. The original Chinese source label remains available below.

Adverse reactions

English translation unavailable. The original Chinese source label remains available below.

Contraindications

English translation unavailable. The original Chinese source label remains available below.

Precautions

English translation unavailable. The original Chinese source label remains available below.

Storage

Keep tightly closed.

Specification

English translation unavailable. The original Chinese source label remains available below.

中文说明书原文Original Chinese source label

批准文号

国药准字H14022935

生产企业

山西华康药业股份有限公司(国产)

适应症

本品用于治疗高血压病。

用法用量

口服,一次2片,一日3次。维持量:一日2片。

不良反应

罗布麻制剂口服常有肠鸣、腹泻,偶有胃痛、口干苦等不良反应,个别病人出现气喘、肝痛;心脏毒性主要是心动过缓和期前收缩。

禁忌

对本品敏感着禁用。

注意事项

1.对伴有糖尿病、痛风的高血压患者应慎用。
2.本品大剂量服用时有中枢镇静作用,驾驶车辆及高空作业者慎用。
3.当药品性状发生改变时禁止服用。

贮藏

密封保存。

规格

复方

证据Evidence

  • 批准文号: 国药准字H14022935
  • rights: 本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.